No effect of high-dose atorvastatin on leukotriene B4 formation from neutrophils in patients treated with coronary bypass surgery: A randomized placebo-controlled double-blinded trial with a crossover design

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 6, 2012, Pages 185-188

  Lysgaard, C ^a   Nielsen, M S ^a   Christensen, J H ^a   Lundbye Christensen, S ^a   Riahi, S ^a,b   Schmidt, E B ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Coronary heart disease; Leukotrienes; Statin

Indexed keywords

ATORVASTATIN; LEUKOTRIENE B4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; EX VIVO STUDY; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIMYCIN; CALCIUM IONOPHORES; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; CORONARY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LEUKOTRIENE B4; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; PYRROLES;

EID: 84870702582     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.09.004     Document Type: Article

References (31)

1. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54:2129-2138.
2. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs Ther. 2009, 23:41-48.
3. Qiu H., Gabrielsen A., Haeggstrom J.Z., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:8161-8166.
4. Cipollone F., Mezzetti A., Stafforini D.M., et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1665-1670.
5. Spanbroek R., Grabner R., Habenicht A.J., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:1238-1243.
6. Mehrabian M., Allayee H., Lusis A.J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 2002, 91:120-126.
7. Helgadottir A., Manolescu A., Topol E.J., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 2006, 38:68-74.
8. Helgadottir A., Gretarsdottir S., MacLeod M.J., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 2005, 76:505-509.
9. Helgadottir A., Manolescu A., Gulcher J.R., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 2004, 36:233-239.
10. Crosslin D.R., Shah S.H., Hauser E.R., et al. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Hum. Genet. 2009, 125:217-229.
11. Dwyer J.H., Allayee H., Mehrabian M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New Engl. J. Med. 2004, 350:29-37.
12. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
13. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J. Am. Coll. Cardiol. 2008, 52:1769-1781.
14. Baigent C., Keech A., Simes R., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
15. Faergeman O., Holme I., Pedersen T.R., et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am. J. Cardiol. 2009, 104:459-463.
16. Uno K., Nicholls S.J. Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?. Curr. Atheroscler. Rep. 2010, 12:14-19.
17. Sadowitz B., Maier K.G., Gahtan V. Basic science review: statin therapy-Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc. Endovasc. Surg. 2010, 44:241-251.
18. Rosenson R.S. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004, 173:1-12.
19. Hsia J., MacFadyen J.G., Monyak J., Ridker P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J. Am. Coll. Cardiol. 2011, 57:1666-1675.
20. Zhou G., Ge S., Liu X., et al. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology 2010, 115:221-228.
21. Kimura M., Kurose I., Russell J., Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1521-1526.
22. Seres I., Foris G., Paragh G., et al. Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia. Metabolism 2005, 54:1147-1154.
23. Gomez-Hernandez A., Sanchez-Galan E., Tunon J., et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am. J. Cardiol. 2008, 102:12-18.
24. Riahi S., Schmidt E.B., Toft E., et al. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. Int. J. Cardiol. 2006, 111:436-441.
25. Assimes T.L., Knowles J.W., Priest J.R., Basu A., Volcik K.A., Southwick A., et al. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum. Genet. 2008, 123:399-408.
26. 4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction. Clin. Sci. (Lond.) 2007, 112:411-416.
27. Gonzalez P., Reguero J.R., Lozano I., Moris C., Coto E. A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int. J. Immunogenet. 2007, 34:127-130.
28. 4 or anti-inflammatory 15-epi-lipoxin a4 production. J. Immunol. 2008, 181:3515-3523.
29. 4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. 2004, 24:369-375.
30. Ford-Hutchinson A.W., Bray M.A., Doig M.V., Shipley M.E., Smith M.J., Leukotriene B. A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286:264-265.
31. Reardon H.T., Zhang J., Kothapalli K.S.D., Kim A.J., Park W.J., Brenna J.T. Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin. Prostaglandins Leukot. Essent. Fatty Acids 2012, 87:25-33.